http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Swati Dasgupta,Ujjal K Ray,Arpita Ghosh Mitra,Deboshree M. Bhattacharyya,Ashis Mukhopadhyay,Priyabrata Das,Sudeshna Gangopadhyay,Sudip Roy,Soma Mukhopadhyay 대한혈액학회 2017 Blood Research Vol.51 No.2
Background: Philadelphia chromosome, a hallmark of chronic myeloid leukemia (CML), plays a key role in disease pathogenesis. It reflects a balanced reciprocal translocation between long arms of chromosomes 9 and 22 involving BCR and ABL1 genes, respectively. An accurate and reliable detection of BCR-ABL fusion gene is necessary for the diagnosis and monitor-ing of CML. Previously, many technologies, most of which are laborious and time consum-ing, have been developed to detect BCR-ABL chimeric gene or chromosome. Methods: A new flow cytometric immunobead assay was used for detection of BCR-ABL fusion pro-teins and applicability, sensitivity, reliability, efficacy and rapidity of this method was evaluated. Results: From February 2009 to January 2014, a total 648 CML patients were investigated for the status of BCR-ABL1 protein. Among them, 83 patients were enrolled for comparative study of BCR-ABL1 positivity by three routinely used procedures like karyotyping, and quantita-tive real time PCR (RT-PCR) as well as immunobead flow cytometry assay. BCR-ABL protein analysis was found consistent, more sensitive (17% greater sensitivity) and reliable than the conventional cytogenetics, as flow cytometry showed 95% concordance rate to RT-PCR. Conclusion: BCR-ABL fusion protein assay using a new flow cytometric immunobead might be useful in the diagnosis and monitoring CML patients.
Swati Dasgupta,Ujjal K Ray,Arpita Ghosh Mitra,Deboshree M. Bhattacharyya,Ashis Mukhopadhyay,Priyabrata Das,Sudeshna Gangopadhyay,Sudip Roy,Soma Mukhopadhyay 대한혈액학회 2017 Blood Research Vol.52 No.2
Background: Philadelphia chromosome, a hallmark of chronic myeloid leukemia (CML), plays a key role in disease pathogenesis. It reflects a balanced reciprocal translocation between long arms of chromosomes 9 and 22 involving BCR and ABL1 genes, respectively. An accurate and reliable detection of BCR-ABL fusion gene is necessary for the diagnosis and monitor-ing of CML. Previously, many technologies, most of which are laborious and time consum-ing, have been developed to detect BCR-ABL chimeric gene or chromosome. Methods: A new flow cytometric immunobead assay was used for detection of BCR-ABL fusion pro-teins and applicability, sensitivity, reliability, efficacy and rapidity of this method was evaluated. Results: From February 2009 to January 2014, a total 648 CML patients were investigated for the status of BCR-ABL1 protein. Among them, 83 patients were enrolled for comparative study of BCR-ABL1 positivity by three routinely used procedures like karyotyping, and quantita-tive real time PCR (RT-PCR) as well as immunobead flow cytometry assay. BCR-ABL protein analysis was found consistent, more sensitive (17% greater sensitivity) and reliable than the conventional cytogenetics, as flow cytometry showed 95% concordance rate to RT-PCR. Conclusion: BCR-ABL fusion protein assay using a new flow cytometric immunobead might be useful in the diagnosis and monitoring CML patients.